Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.
Glatiramer acetate
Innate immunity
Interferon beta-1a
Monocytes
Multiple sclerosis
Journal
European neurology
ISSN: 1421-9913
Titre abrégé: Eur Neurol
Pays: Switzerland
ID NLM: 0150760
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
01
2023
accepted:
03
07
2023
medline:
3
11
2023
pubmed:
21
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD). A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.
Identifiants
pubmed: 37473734
pii: 000532022
doi: 10.1159/000532022
pmc: PMC10623392
doi:
Substances chimiques
Glatiramer Acetate
5M691HL4BO
Interferon beta-1a
XRO4566Q4R
Interferon-beta
77238-31-4
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-340Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Clin Dev Immunol. 2013;2013:413465
pubmed: 24174969
Neurologist. 2007 Mar;13(2):45-56
pubmed: 17351524
J Neuroinflammation. 2012 Jan 02;9:1
pubmed: 22212381
J Neuroimmunol. 2004 Jan;146(1-2):176-88
pubmed: 14698861
J Neuroimmunol. 2010 Apr 15;221(1-2):7-14
pubmed: 19931190
Curr Med Res Opin. 2021 Apr;37(4):589-596
pubmed: 33538199
J Neuroimmunol. 2017 Mar 15;304:11-20
pubmed: 28007303
Lancet Neurol. 2015 Apr;14(4):406-19
pubmed: 25792099
Immunity. 2017 Jun 20;46(6):943-956
pubmed: 28636961
PLoS One. 2015 Mar 10;10(3):e0116511
pubmed: 25756363
Trends Pharmacol Sci. 2019 Jul;40(7):482-494
pubmed: 31130220
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Neuroimmunol. 2018 May 15;318:1-7
pubmed: 29606295
Front Cell Neurosci. 2019 Jul 31;13:355
pubmed: 31427930
N Engl J Med. 2006 Mar 2;354(9):942-55
pubmed: 16510748
Acta Neurol Scand. 2017 Nov;136 Suppl 201:10-14
pubmed: 29068495
Expert Opin Drug Deliv. 2020 May;17(5):719-724
pubmed: 32315204
Annu Rev Immunol. 2005;23:683-747
pubmed: 15771584
Parasite Immunol. 2010 Jan;32(1):1-19
pubmed: 20042003
Mult Scler Relat Disord. 2021 Aug;53:103082
pubmed: 34166982